Is there a clinical benefit of S100B for the management of mild traumatic brain injury?

This study emphasizes the need for careful consideration when integrating S100B into mTBI management protocols for patients with a low risk for IHs. The low specificity in a younger population suggests that the risks of radiation from unnecessary CCT studies may outweigh the benefits. Although international guidelines were followed, integrating S100B into the mTBI protocol did not reduce CCT use as expected. In the absence of ongoing or new onset of neurological symptoms, elevated S100B values should not trigger CCT studies in a low-risk mTBI population.